Get the Stockscreener App
1.85
0.54%
0.01
Caribou Biosciences Inc stock is traded at $1.85, with a volume of 1.40M.
It is up +0.54% in the last 24 hours and down -21.94% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
See More
Previous Close:
$1.84
Open:
$1.84
24h Volume:
1.40M
Relative Volume:
0.91
Market Cap:
$172.28M
Revenue:
$34.48M
Net Income/Loss:
$-102.07M
P/E Ratio:
-1.2671
EPS:
-1.46
Net Cash Flow:
$-104.90M
1W Performance:
-6.57%
1M Performance:
-21.94%
6M Performance:
+41.22%
1Y Performance:
-11.48%
1-Day Range:
$1.82
$1.965
1-Week Range:
$1.73
$2.00
52-Week Range:
$0.66
$2.9995
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.85 | 174.14M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
Chart Analysts Warn of Resistance Near Caribou Biosciences Inc. PriceJuly 2025 Patterns & Free Low Drawdown Momentum Trade Ideas - beatles.ru
Caribou Biosciences reports Q2 EPS (35c), one estimate (42c) - MSN
Momentum Screeners Rank Caribou Biosciences, Inc. in Top 5 TodayJuly 2025 Update & Low Risk Growth Stock Ideas - thegnnews.com
Caribou Biosciences Inc. Pullback Analyzed — Is It Time to Exit2025 Sector Review & Short-Term High Return Ideas - kangso.co.kr
Caribou Biosciences Inc.’s Price Action Aligns with Quant SignalsWeekly Trade Review & AI Powered Buy/Sell Recommendations - beatles.ru
How does Caribou Biosciences Inc. score in quality rankingsCPI Data & Expert Verified Movement Alerts - 선데이타임즈
Is Caribou Biosciences Inc. Forming a Bottom PatternGlobal Markets & Reliable Entry Point Alerts - metal.it
Truist Financial analyst assigns Buy rating to Caribou Biosciences with $3.50 price target. - AInvest
RBC Capital Maintains Buy Rating for Caribou Biosciences with $10 Price Target - AInvest
Caribou Biosciences: Strong Clinical Progress and Financial Health Justify Buy Rating with $3.00 Target - AInvest
Caribou Biosciences: Promising Clinical Progress and Strong Financial Position Justify Buy Rating - TipRanks
Caribou Biosciences Reports Wider Q2 Loss Amid Increased R&D Spending - AInvest
Caribou Biosciences Reports Increased Losses Amid R&D Efforts - TipRanks
Navigating the Storm: Caribou Biosciences' Strategic Rebalancing and the Road to Gene-Editing Dominance - AInvest
Caribou Biosciences earnings beat by $0.04, revenue topped estimates - Investing.com Canada
Caribou Biosciences Q2 2025: $184mln cash, H2 2027 funding, CB-010 & CB-011 data in H2 2025. - AInvest
Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
Is Caribou Biosciences Inc. Forming a Consolidation BaseTrade Setups With Clear Risk Limits Highlighted - beatles.ru
Caribou Biosciences CRBU Q2 2025 Earnings Preview Downside Risk Amid Clinical Trial Delays - AInvest
Sentiment Tools Show Shift in Trader Mood on Caribou Biosciences Inc.Exit Ready Momentum Stock Watchlist Expanded - beatles.ru
Published on: 2025-08-05 08:29:24 - metal.it
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. Lawsuit – CRBU - ACCESS Newswire
Caribou Biosciences Inc. Price Targets Raised After ReboundWeekly Hot Picks With Buy Confidence Released - metal.it
What analysts say about Caribou Biosciences Inc. stockInvest confidently with professional advice - Jammu Links News
Caribou Biosciences Inc. Stock Analysis and ForecastTremendous growth potential - Jammu Links News
What makes Caribou Biosciences Inc. stock price move sharplyMaximize your returns with smart trade entries - Jammu Links News
Is Caribou Biosciences Inc. stock overvalued or undervaluedBuild wealth with steady, reliable stocks - Jammu Links News
What are the latest earnings results for Caribou Biosciences Inc.Achieve consistent double-digit growth rates - Jammu Links News
How does Caribou Biosciences Inc. compare to its industry peersBuild wealth steadily with expert advice - Jammu Links News
Is it the right time to buy Caribou Biosciences Inc. stockAchieve breakthrough investment performance - Jammu Links News
How strong is Caribou Biosciences Inc. company’s balance sheetInvest in high-yield stocks with confidence - Jammu Links News
Caribou Biosciences Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
Caribou Biosciences Inc. stock prediction for this weekPortfolio Diversification Stock Ideas From Experts - metal.it
How Interest Rate Changes Impact Caribou Biosciences Inc. Stock PerformanceLong Hold Safe Return Strategy Reviewed - metal.it
Why Caribou Biosciences Inc. stock attracts strong analyst attentionTechnical Entry Strategy for Beginners Explained - beatles.ru
How many analysts rate Caribou Biosciences Inc. as a “Buy”Earnings Report Entry Points For Fast Growth - Jammu Links News
Why is Caribou Biosciences Inc. stock attracting strong analyst attentionHigh-velocity gains - Jammu Links News
What institutional investors are buying Caribou Biosciences Inc. stockMaximize returns with strategic trading plans - Jammu Links News
What is Caribou Biosciences Inc. company’s growth strategyCapitalize on fast-growing investment opportunities - jammulinksnews.com
Published on: 2025-07-28 05:44:44 - Jammu Links News
CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Caribou Biosciences Inc Stock (CRBU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MCCLUNG BARBARA G | Chief Legal Officer |
Feb 21 '25 |
Sale |
1.35 |
3,564 |
4,811 |
443,502 |
| Khan Ruhi Ahmad | Chief Business Officer |
Feb 21 '25 |
Sale |
1.35 |
3,564 |
4,811 |
66,936 |
| Kanner Steven | Chief Scientific Officer |
Feb 21 '25 |
Sale |
1.35 |
3,564 |
4,811 |
431,556 |
| Ryali Sriram | Chief Financial Officer |
Jan 29 '25 |
Buy |
1.42 |
17,360 |
24,651 |
17,360 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):